September is National Sickle Cell Awareness Month: New Hope Through Innovation & Policy

Each September, National Sickle Cell Awareness Month shines a spotlight on the realities of sickle cell disease (SCD)—a painful and life-threatening genetic condition that disproportionately affects Black and African American communities. More than 9,000 Californians live with SCD, joining 100,000 people across the United States and more than 20 million worldwide.

While SCD has long been overlooked and stigmatized, advances in science are transforming what is possible. Just last year, the U.S. Food and Drug Administration approved the first-ever gene therapies for sickle cell disease—Casgevy by Vertex Pharmaceuticals and Lyfgenia by bluebird bio. These groundbreaking treatments aim to correct the root cause of SCD, offering patients the potential for longer, healthier, and more productive lives.

California’s life science industry has been central to this progress. Our state is home to pioneering researchers, cutting-edge biotechnology companies, and world-class medical centers that are advancing therapies from discovery through clinical trials. Yet innovation alone is not enough. Equitable access, robust funding for research, and policies that support both patient care and the biotechnology ecosystem are critical to ensuring breakthroughs reach those who need them most.

State policymakers play a vital role in sustaining this momentum. Continued investment in biomedical research, workforce training, and healthcare infrastructure helps California remain a global leader in life sciences. At the same time, state action to address health disparities, expand access to advanced treatments, and support early-stage innovation will ensure patients benefit directly from scientific progress.

This Sickle Cell Awareness Month, the California Biotechnology Foundation calls on policymakers to stand with patients, caregivers, advocates, and the life science community. Together, we can ensure that the promise of innovation translates into real hope, equity, and cures for Californians living with sickle cell disease.

For more information visit the Sickle Cell Disease Foundation or Networking California for Sickle Cell Care, organizations dedicated to bringing greater awareness to sickle cell disease.

Celebrating Hispanic Heritage Month: Honoring Hispanic Leaders in Life Sciences

As we celebrate Hispanic Heritage Month (September 15 – October 15, 2025), the California Biotechnology Foundation (CBF) recognizes the Hispanic leaders advancing biopharma and life sciences in California. Their contributions reflect not only scientific excellence but also a commitment to equity, innovation, and community impact. These leaders are helping strengthen our state’s life sciences ecosystem, expanding opportunity, and inspiring the next generation of researchers and innovators.

Grace E. Colón, Ph.D., Co-Founder & CEO, Inaya Therapeutics
Dr. Grace Colón is a pioneering force in biotechnology, leading Inaya Therapeutics with a vision rooted in both science and compassion. Her work in innovative therapeutics exemplifies what it means to be a changemaker in the biotech world.

Miguel Motta, VP of Strategic Operations & San Diego Head, Biocom California
Through his leadership at Biocom California, Miguel Motta strengthens the state’s biotech ecosystem, supports local innovation, and fosters collaboration across industries.

H. Puentes, President & CEO, San Diego Squared (SD2)
H. Puentes is building pathways for diverse talent in STEM through his work at SD2. His efforts focus on creating equity in biotech and empowering the next generation of scientists.

Dr. Diana Ramos, California Surgeon General
A strong advocate for public health, Dr. Diana Ramos is advancing health equity across California. As the state’s top medical officer, her leadership focuses on strengthening communities through inclusive health strategies.

Esteban Santos, Executive Vice President of Operations, Amgen
Esteban Santos drives operational excellence at one of the world’s leading biotechnology companies. His leadership at Amgen reflects a strong commitment to innovation and global impact.

Dr. Anabella Villalobos, Chief Scientific Officer, Metaphore Biotechnologies
A passionate scientist and leader, Dr. Villalobos is driving therapeutic innovation at Metaphore Bio. Her career reflects a commitment to discovery, mentorship, and breaking barriers in science.

Willie Zuñiga, Emeritus President, Grifols Biologicals
A longtime advocate for workforce development and community engagement, Willie Zuñiga has left a lasting legacy in Southern California’s biotech landscape. His efforts continue to uplift underrepresented communities in STEM.